What strategy has been developed to mitigate relugolix-induced BMD loss?
Label:chem
Topic
Prolonged estrogen deprivation leads to unacceptable bone loss, so add-back hormone therapy is required for long-term use of GnRH antagonists.
Answer
A once-daily combination tablet containing 40 mg relugolix, 1 mg estradiol (E2), and 0.5 mg norethisterone acetate (NETA) was formulated. The low-dose E2 replaces enough estrogen to protect bone, while NETA provides endometrial protection against unopposed estrogen stimulation.
Return to Home
Chemical List
Knowledge you may be interested in